| Similar Articles |
|---|
 |
Chemistry World
August 31, 2011
Hayley Birch |
Smallpox vaccine virus puts cancer in its sights The results of a human cancer therapy trial show for the first time that tumors can be targeted and infected by engineered viruses, without damage to surrounding tissues.   |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
November 2, 2004
Charly Travers |
Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer. |
HHMI Bulletin
Nov 2010
Amy Maxmen |
Driving the Immune System to Attack Cancer A researcher's longtime efforts to drive T cells to attack tumors hits pay dirt. |
Chemistry World
June 9, 2008
Simon Hadlington |
Artificial virus silences genes Scientists in Korea have created an artificial virus that can target the nucleus of cancer cells and knock out specific genes. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
BusinessWeek
May 9, 2005
Catherine Arnst |
Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents. |
HHMI Bulletin
Nov 2010 |
Fusion genes that drive solid tumors are a new target for cancer therapies The success of Gleevec and related drugs has inspired researchers to step up their hunt for the molecular defects underlying other cancers. |
HHMI Bulletin
May 2010
Sarah C.P. Williams |
Lab-Grown Liver New cell culture system solves problem of growing liver cells. |
BusinessWeek
May 12, 2011
Robert Langreth |
Big Pharma Bets on a Novel Cancer Cure Research in epigenetics is booming. The payoff could be in the billions. |
Chemistry World
January 6, 2011
Laura Howes |
Using HIV against itself US researchers have developed a 'Trojan horse' molecule that uses HIV to trigger the release of a drug that destroys the virus. |
Chemistry World
November 11, 2015
Maria Burke |
Viral cancer therapy approved in the US The first virus therapy to target cancer has been approved in the US. Its main target will be melanoma, the most aggressive form of skin cancer. |
Scientific American
January 2009
Melinda Wenner |
Does Herpes Cause a Form of Sen. Edward Kennedy s Brain Cancer? New evidence points to a link between the herpesvirus and the deadly cancer glioblastoma |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
The Motley Fool
May 8, 2009
Brian Orelli |
Investing Against Breast Cancer Many companies are interested in both a cure and a large lucrative market. Which are the best investments now in this sector? |
The Motley Fool
June 29, 2011
Brian Orelli |
4 Immunotherapies to Watch Just don't go all-in. |
BusinessWeek
April 30, 2007
Catherine Arnst |
Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced. |
Chemistry World
March 4, 2011
Elinor Richards |
Laser treatment for late-stage cancer Scientists from China, the US and Peru claim to have successfully treated late-stage breast cancer patients using laser immunotherapy to stimulate patients' own immune systems to fight the cancer. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument. |
Pharmaceutical Executive
June 1, 2007 |
Thoughtleader: Stephen Sherwin, Cell Genesys Cell Genesys has been able to raise enough capital to gamble on what it CEO believes could be the future's most promising therapies, including gene activation, immunotherapy, and oncolytic virus therapy. |
Scientific American
January 2009
Charles Q. Choi |
Do White Blood Cells Make Cancer Deadly? The ability to spread underlies the killing power of cancer. The process occurs, John Pawelek thinks, when tumor cells fuse with white blood cells -- an idea that, if right, could yield new therapies |
The Motley Fool
April 28, 2009
Brian Orelli |
Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off. |
HHMI Bulletin
Aug 2011
Richard Saltus |
T-Cell Booster Kits A bioengineer remodels cell surfaces to prod the immune system. |
Managed Care
June 2007
Thomas Morrow |
Dendritic Cell Vaccine Hits FDA Roadblock Questions about study design and analysis prompted the FDA to postpone action on Provenge, a treatment for advanced prostate cancer. |
Pharmaceutical Executive
April 1, 2006
Joanna Breitstein |
HBA Woman of the Year: Susan Desmond-Hellman There are people who hope cancer, one day, will become a manageable disease. Then there are those who know it. Meet Susan Desmond-Hellmann. |
The Motley Fool
May 21, 2007
Mike Havrilla |
Allos Aligned for Success With two drugs that both sport reasonable chances of positive clinical data and FDA approval, biotech investors should take a look at Allos -- before any potential good news rolls in. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
The Motley Fool
November 18, 2004
Charly Travers |
A Glimpse of Bristol-Myers' Portfolio Late-stage drugs are crucial for a company beset with patent losses. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
Reactive Reports
Issue 56
Jeffrey Krise |
A Basic Approach to Chemotherapy Chemists have found a way to attack malignant cells with an anticancer drug, while sparing healthy cells. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
The Motley Fool
April 29, 2005
Tim Hanson |
Genentech's Promising Future Cancer drug Avastin is finding new uses. How will outside forces affect its potential? Investors take note. |
Chemistry World
July 28, 2009
Michael Gross |
DNA to direct and switch off chemo Researchers in the US have developed a new approach to cancer chemotherapy using short DNA strands to help target delivery of the drug directly to cancer cells, and 'call it off' should problems arise. |
Bio-IT World
August 13, 2003
Malorye Branca |
Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm. |
Wired
August 2003
Jennifer Kahn |
The End of Cancer (As we Know it) Diagnosis. Chemotherapy. Radiation. Slow painful death. No more. A new era of cancer treatment is dawning. Meet three scientists who are using the revelations of the Human Genome Project to reshape medicine. |
The Motley Fool
July 30, 2007
Brian Orelli |
Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug. |
BusinessWeek
May 23, 2005
Catherine Arnst |
If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer. |
AskMen.com
Dave Golokhov |
Men And Skin Cancer Men are three times more likely to develop skin cancer than women. While that's not breaking news, scientists have struggled to figure out the reason why men are more susceptible, and there appears to be a breakthrough. |
The Motley Fool
July 6, 2009
Brian Orelli |
Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer. |
Bio-IT World
August 13, 2002
Kevin Davies |
Curtailing the Cancerous Cell The highly touted drug Gleevec unleashed new hope in the battle against cancer. Now a group of new drugs, working on the same principle, are showing even greater promise in treating leukemia. |
The Motley Fool
June 25, 2009
Brian Orelli |
Pfizer Gets a Double After a couple of disappointing trials for Pfizer's Sutent, investors get some good news about the drug. |
The Motley Fool
August 9, 2010
Luke Timmerman |
Kaleetan Seeks to Stand on Dendreon's Shoulders Kaleetan Pharmaceuticals tries to improve upon Dendreon's breakthrough cancer drug. |
The Motley Fool
October 27, 2006
Jack Uldrich |
Nanotech and the War on Cancer New imaging advances in nanotechnology will help speed cancers' end. What does it mean for investors? |
BusinessWeek
October 6, 2003
Arlene Weintraub |
Drug Development, Genentech Style Its promising colon cancer fighter Avastin is a prime example of how the biotech "keeps following the science." |
American Family Physician
February 1, 2004 |
Penile Cancer What is cancer?... How does my doctor check for cancer?... How is penile cancer treated? |
The Motley Fool
June 9, 2010
Brian Orelli |
ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology. |
BusinessWeek
June 21, 2004
Catherine Arnst |
Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs. |
HHMI Bulletin
Aug 2011
Cassandra Willyard |
A Faster Knockout With a virus, a needle, and an ultrasound machine, researchers have drastically cut the time it takes to disable a gene in mice. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Non-Small-Cell Lung Cancer: Targeting Pathways and Patients Although the most common cancer worldwide, lung cancer remains poorly treated, with the highest mortality rate. |
